PharmaMar announces the approval of Aplidin in Australia for the treatment of multiple myeloma

PharmaMar

11 December 2018 - PharmaMar has licensed Aplidin to its partner, STA, in Australia, New Zealand and several Southeast Asian countries.

PharmaMar announces that the Australian Regulatory Agency (TGA) has informed STA that Aplidin (plitidepsin) has been approved for the treatment of multiple myeloma in combination with dexamethasone.

Aplidin will be available to patients who have failed or are resistant to other therapies, after the TGA decision to approve Aplidin before any other country.

The indication has been approved for the treatment of patients that relapse after three lines of treatment, including proteasome inhibitors or immunomodulators. It can also be administered as third-line treatment, when the patient has already received two prior lines and is refractory or intolerant to proteasome inhibitors or immunomodulators.

Read PharmaMar press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Australia